Pfizer’s Inlyta Receives FDA Approval for Patients With Advanced Kidney Cancer

by Kathy Jones on  January 28, 2012 at 7:53 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

Pfizer's cancer drug Inlyta has been approved by the US Food and Drug Administration to be used in treating patients with advanced kidney cancer.
 Pfizer’s Inlyta Receives FDA Approval for Patients With Advanced Kidney Cancer
Pfizer’s Inlyta Receives FDA Approval for Patients With Advanced Kidney Cancer

The health regulator said that the drug can be used to treat patients who do not respond to any other drugs currently available in treating advanced kidney cancer.

The director of the FDA's office of oncology products, Richard Pazdur announced that Inlyta was the seventh drug approved by the agency to treat advanced kidney cancer and the latest approval will provide patients with multiple treatment options.

While Pfizer will be hoping that the approval will help boost their flagging sales following continued poor performance of its cholesterol drug Lipitor, market analysts said that Inlyta will struggle to gain a foothold in a congested market and predicted peak sales of $600 million.


Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Cancer and Homeopathy Urinary Stones In Children Vesico-Ureteric Reflux Causing UTI in Children Hydronephrosis / Antenatal Counseling Kidney Disease Cancer Facts Cancer Tattoos A Body Art Kidney Hematuria 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive